Health and Weight Management | Market Size, Share & Growth Report 2024-2029

North America holds the best-measured disease burden, the largest commercial activity and the decisive coverage question. The National Center for Health Statistics reported adult obesity at 40.3% and severe obesity at 9.7% for August 2021 to August 2023, with a further 31.7% overweight, and obesity reaching 46.4% among adults aged 40 to 59. Severe obesity rose from 7.7% to 9.7% over the preceding decade even as overall obesity held steady, which concentrates demand at the end of the spectrum where intervention is most intensive. Eli Lilly reported approximately USD 36.5 billion in combined tirzepatide sales for 2025. The unresolved issue is federal coverage. The Centers for Medicare & Medicaid Services proposed Part D and Medicaid coverage of anti-obesity medications on 26 November 2024 and declined to finalise it on 4 April 2025. The largest public payer still does not cover them for obesity. No regional market size, revenue or growth figure for North America was identified in the sources reviewed for this report. The regional position therefore rests on documented disease concentration and on the coverage decision described above rather than on a measured market figure.

Europe is the base of one of the two companies that define the pharmacological segment, since Novo Nordisk A/S is headquartered in Denmark and markets semaglutide as Wegovy, and of Nestlé S.A. in Switzerland, whose Health Science division runs the Optifast medically supervised meal-replacement programme. National health systems make coverage decisions individually rather than through a single mechanism, so access varies by country in a way that has no direct equivalent in the United States federal position. No Europe-wide prevalence dataset comparable to the National Center for Health Statistics series, and no European reimbursement decision on anti-obesity medication equivalent to the Medicare proposal, was identified for this analysis. The regional position therefore rests on corporate presence and manufacturing rather than on measured regional demand.

Asia Pacific is served by the same approved medicines and the same meal-replacement programmes, since Optifast is described as available in key markets worldwide and both approved GLP-1 receptor agonists are marketed internationally. No region-specific prevalence survey, reimbursement decision or revenue disclosure for weight management was identified for Asia Pacific in the sources reviewed. Body mass index thresholds used to define obesity differ in several Asian populations from those used in the United States data, which means prevalence figures are not directly comparable across regions and a straightforward transfer of the 40.3% United States figure would be incorrect. Recording that difference is more useful than asserting a regional ranking that the available evidence does not support.

No Latin America-specific prevalence survey, reimbursement decision, provider disclosure or revenue figure for weight management was identified. The supplement and meal-replacement categories reach the region through direct selling, and Herbalife Ltd. operates a distributor model across multiple markets, but the company reports revenue globally rather than by region in the sources reviewed. Without regional prevalence data or a coverage decision comparable to the Medicare proposal, no ranking, share or growth claim for this region would be supported by verified evidence.

Middle East & Africa has the least published evidence of any supplied region for this market. No regional prevalence dataset, reimbursement mechanism, distribution figure or company disclosure specific to weight management was identified in the sources reviewed. Because access to GLP-1 receptor agonists depends on both regulatory approval and ability to pay, and because neither was documented at regional level in these sources, the balance between pharmacotherapy and the supplement and programme categories cannot be described here from verified evidence.